Bibliografías temáticas / Biomarkers

Literatura académica sobre el tema "Biomarkers"

Autor: Grafiati
Publicado: 4 de junio de 2021
Última modificación: 30 de julio de 2024

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Índice

Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Biomarkers".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Artículos de revistas sobre el tema "Biomarkers"

1

Mitterhauser, Markus y Wolfgang Wadsak. "Imaging Biomarkers or Biomarker Imaging?" Pharmaceuticals 7, n.º 7 (25 de junio de 2014): 765–78. http://dx.doi.org/10.3390/ph7070765.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Zhao, Xuemei, Vijay Modur, Leonidas N. Carayannopoulos y Omar F. Laterza. "Biomarkers in Pharmaceutical Research". Clinical Chemistry 61, n.º 11 (1 de noviembre de 2015): 1343–53. http://dx.doi.org/10.1373/clinchem.2014.231712.

Texto completo
Resumen
Abstract BACKGROUND Biomarkers are important tools in drug development and are used throughout pharmaceutical research. CONTENT This review focuses on molecular biomarkers in drug development. It contains sections on how biomarkers are used to assess target engagement, pharmacodynamics, safety, and proof-of-concept. It also covers the use of biomarkers as surrogate end points and patient selection/companion diagnostics and provides insights into clinical biomarker discovery and biomarker development/validation with regulatory implications. To survey biomarkers used in drug development—acknowledging that many pharmaceutical development biomarkers are not published—we performed a focused PubMed search employing “biomarker” and the names of the largest pharmaceutical companies as keywords and filtering on clinical trials and publications in the last 10 years. This yielded almost 500 entries, the majority of which included disease-related (approximately 60%) or prognostic/predictive (approximately 20%) biomarkers. A notable portion (approximately 8%) included HER2 (human epidermal growth factor receptor 2) testing, highlighting the utility of biomarkers for patient selection. The remaining publications included target engagement, safety, and drug metabolism biomarkers. Oncology, cardiovascular disease, and osteoporosis were the areas with the most citations, followed by diabetes and Alzheimer disease. SUMMARY Judicious biomarker use can improve pharmaceutical development efficiency by helping to select patients most appropriate for treatment using a given mechanism, optimize dose selection, and provide earlier confidence in accelerating or discontinuing compounds in clinical development. Optimal application of biomarker technology requires understanding of candidate drug pharmacology, detailed modeling of biomarker readouts relative to pharmacokinetics, rigorous validation and qualification of biomarker assays, and creative application of these elements to drug development problems.
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Grandjean, P. "Biomarkers in epidemiology". Clinical Chemistry 41, n.º 12 (1 de diciembre de 1995): 1800–1803. http://dx.doi.org/10.1093/clinchem/41.12.1800.

Texto completo
Resumen
Abstract A biomarker is a measurable event occurring in a biological system, such as the human body. In environmental epidemiology, a biomarker represents a subclinical and reversible change; it is not a diagnostic test, but an indicator that an early change has occurred that could later lead to clinical disease. Although some biomarkers may belong to more than one class, they are often separated into biomarkers of exposure, biomarkers of effect, and biomarkers of susceptibility. Biomarkers can be used to classify and quantify environmental exposures and their related effects, and many methods may be applicable in toxicological experiments as well as in epidemiology. Accordingly, biomarker epidemiology is undergoing rapid development and expansion and is becoming one of the most promising areas of environmental research. Although expanded applications should be encouraged, many biomarkers are poorly characterized, and attention should be paid to defining their properties in detail.
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Wishart, David S., Brendan Bartok, Eponine Oler, Kevin Y. H. Liang, Zachary Budinski, Mark Berjanskii, AnChi Guo, Xuan Cao y Michael Wilson. "MarkerDB: an online database of molecular biomarkers". Nucleic Acids Research 49, n.º D1 (27 de noviembre de 2020): D1259—D1267. http://dx.doi.org/10.1093/nar/gkaa1067.

Texto completo
Resumen
Abstract MarkerDB is a freely available electronic database that attempts to consolidate information on all known clinical and a selected set of pre-clinical molecular biomarkers into a single resource. The database includes four major types of molecular biomarkers (chemical, protein, DNA [genetic] and karyotypic) and four biomarker categories (diagnostic, predictive, prognostic and exposure). MarkerDB provides information such as: biomarker names and synonyms, associated conditions or pathologies, detailed disease descriptions, detailed biomarker descriptions, biomarker specificity, sensitivity and ROC curves, standard reference values (for protein and chemical markers), variants (for SNP or genetic markers), sequence information (for genetic and protein markers), molecular structures (for protein and chemical markers), tissue or biofluid sources (for protein and chemical markers), chromosomal location and structure (for genetic and karyotype markers), clinical approval status and relevant literature references. Users can browse the data by conditions, condition categories, biomarker types, biomarker categories or search by sequence similarity through the advanced search function. Currently, the database contains 142 protein biomarkers, 1089 chemical biomarkers, 154 karyotype biomarkers and 26 374 genetic markers. These are categorized into 25 560 diagnostic biomarkers, 102 prognostic biomarkers, 265 exposure biomarkers and 6746 predictive biomarkers or biomarker panels. Collectively, these markers can be used to detect, monitor or predict 670 specific human conditions which are grouped into 27 broad condition categories. MarkerDB is available at https://markerdb.ca.
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

De Jesus, J. R. y Marco Arruda. "Human disease biomarkers: challenges, advances, and trends in their validation". Journal of Integrated OMICS 11, n.º 2 (29 de diciembre de 2021): 16–28. http://dx.doi.org/10.5584/jiomics.v11i2.207.

Texto completo
Resumen
Biomarkers are important tools in the medical field, once they allow better prediction, characterization, and treatment of diseases. In this scenario, it is essential that biomarkers are highly accurate. Thus, biomarker validation is an essential part of ensuring the effectiveness of a biomarker. Validation of biomarkers is the process by which biomarkers are evaluated for accuracy and consistency, as well as their ability to inform the condition of health or disease. Although, there is no unique measure that can be used to determine the validity for all biomarkers, there are general criteria that all biomarkers must meet to be useful. In this work, we review the definition of biomarkers and discuss the validity components. We then critically discuss the main methods used to validate biomarkers and consider some examples of biomarkers of the diseases which most killer in the world (cardiovascular diseases, cancer, and viral infections), highlighting the potential biochemical pathways of these biomarkers in the biological system. In addition, we also comment on the omic strategies used in the biomarker discovery process and conclude with information about perspectives in biomarker validation through imaging techniques.
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Dean, Brian. "Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers". Schizophrenia Research and Treatment 2011 (2011): 1–10. http://dx.doi.org/10.1155/2011/614730.

Texto completo
Resumen
The search for clinically useful biomarkers has been one of the holy grails of schizophrenia research. This paper will outline the evolving notion of biomarkers and then outline outcomes from a variety of biomarkers discovery strategies. In particular, the impact of high-throughput screening technologies on biomarker discovery will be highlighted and how new or improved technologies may allow the discovery of either diagnostic biomarkers for schizophrenia or biomarkers that will be useful in determining appropriate treatments for people with the disorder. History tells those involved in biomarker research that the discovery and validation of useful biomarkers is a long process and current progress must always be viewed in that light. However, the approval of the first biomarker screen with some value in predicting responsiveness to antipsychotic drugs suggests that biomarkers can be identified and that these biomarkers that will be useful in diagnosing and treating people with schizophrenia.
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Weickert, Cynthia S., Thomas W. Weickert, Anil Pillai y Peter F. Buckley. "Biomarkers in Schizophrenia: A Brief Conceptual Consideration". Disease Markers 35 (2013): 3–9. http://dx.doi.org/10.1155/2013/510402.

Texto completo
Resumen
Biomarkers have been sought after in the field of schizophrenia research for decades. In this paper, we discuss some of the concepts around developing biomarkers in an effort to understand why the use of biomarkers for schizophrenia has not been realized. In particular, we address the following 4 questions. Why would we need a diagnostic biomarker for schizophrenia? How is a biomarker typically defined and how does that influence the discovery of biomarkers in schizophrenia? What is the best use of biomarkers in schizophrenia? Do any biomarkers for schizophrenia currently exist? Thus, while we suggest that no biomarker currently exists for schizophrenia, the heterogeneity associated with schizophrenia will most likely need to be taken into account which will result in multiple biomarkers that identify the multiple underlying pathophysiological processes involved in schizophrenia. Therefore, much additional work will be required prior to obtaining any well-established biomarkers for schizophrenia.
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Califf, Robert M. "Biomarker definitions and their applications". Experimental Biology and Medicine 243, n.º 3 (febrero de 2018): 213–21. http://dx.doi.org/10.1177/1535370217750088.

Texto completo
Resumen
Biomarkers are critical to the rational development of medical therapeutics, but significant confusion persists regarding fundamental definitions and concepts involved in their use in research and clinical practice, particularly in the fields of chronic disease and nutrition. Clarification of the definitions of different biomarkers and a better understanding of their appropriate application could result in substantial benefits. This review examines biomarker definitions recently established by the U.S. Food and Drug Administration and the National Institutes of Health as part of their joint Biomarkers, EndpointS, and other Tools (BEST) resource. These definitions are placed in context of their respective uses in patient care, clinical research, or therapeutic development. We explore the distinctions between biomarkers and clinical outcome assessments and discuss the specific definitions and applications of diagnostic, monitoring, pharmacodynamic/response, predictive, prognostic, safety, and susceptibility/risk biomarkers. We also explore the implications of current biomarker development trends, including complex composite biomarkers and digital biomarkers derived from sensors and mobile technologies. Finally, we discuss the challenges and potential benefits of biomarker-driven predictive toxicology and systems pharmacology, the need to ensure quality and reproducibility of the science underlying biomarker development, and the importance of fostering collaboration across the entire ecosystem of medical product development. Impact statement Biomarkers are critical to the rational development of medical diagnostics and therapeutics, but significant confusion persists regarding fundamental definitions and concepts involved in their use in research and clinical practice. Clarification of the definitions of different biomarker classes and a better understanding of their appropriate application could yield substantial benefits. Biomarker definitions recently established in a joint FDA-NIH resource place different classes of biomarkers in the context of their respective uses in patient care, clinical research, or therapeutic development. Complex composite biomarkers and digital biomarkers derived from sensors and mobile technologies, together with biomarker-driven predictive toxicology and systems pharmacology, are reshaping development of diagnostic and therapeutic technologies. An approach to biomarker development that prioritizes the quality and reproducibility of the science underlying biomarker development and incorporates collaborative regulatory science involving multiple disciplines will lead to rational, evidence-based biomarker development that keeps pace with scientific and clinical need.
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Birkeland, Marian L. y Joan S. McClure. "Optimizing the Clinical Utility of Biomarkers in Oncology: The NCCN Biomarkers Compendium". Archives of Pathology & Laboratory Medicine 139, n.º 5 (21 de octubre de 2014): 608–11. http://dx.doi.org/10.5858/arpa.2014-0146-ra.

Texto completo
Resumen
Context The rapid development of commercial biomarker tests for oncology indications has led to confusion about which tests are clinically indicated for oncology care. By consolidating biomarker testing information recommended within National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines), the NCCN Biomarkers Compendium aims to ensure that patients have access to appropriate biomarker testing based on the evaluations and recommendations of the expert NCCN panel members. Objectives To present the recently launched NCCN Biomarkers Compendium. Data Sources Biomarker testing information recommended within NCCN Clinical Treatment Guidelines as well as published resources for genetic and biological information. Conclusions The NCCN Biomarkers Compendium is a continuously updated resource for clinicians who need access to relevant and succinct information about biomarker testing in oncology and is linked directly to the recommendations provided within the NCCN Clinical Practice Guidelines.
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Prentice, Ross L. "Criteria for Acceptable Dietary Intake Biomarkers". Cancer Epidemiology, Biomarkers & Prevention 31, n.º 6 (1 de junio de 2022): 1151–53. http://dx.doi.org/10.1158/1055-9965.epi-22-0180.

Texto completo
Resumen
Abstract Dietary intake biomarkers that can be written as actual intake, plus ‘error’ that is independent of actual intake and confounding factors can substitute for actual intake in disease association analyses. Also, such biomarkers can be used to develop calibration equations using self-reported diet and participant measures, and biomarker-calibrated intakes can be calculated in larger cohorts for use in disease association analyses. Criteria for biomarkers, and for biomarker-calibrated intakes, arise by working back from properties needed for valid disease association analyses. Accordingly, arguments for a potential biomarker are strengthened if error components are small relative to actual intakes, and important sources of reduced sensitivity or specificity are not apparent. Feeding study biomarker development can then involve regression of actual intake on putative biomarkers, with regression R2 values playing a role in biomarker evaluation. In comparison, ‘predictive’ biomarker status, as argued in this issue by Freedman and colleagues for 24-hour urinary sucrose plus fructose as biomarker for total sugars, involves regression of potential biomarker on actual intake and other variables, with parameter stability across populations and limited within-person variability as criteria. The choice of criteria for biomarkers and for biomarker-calibrated intakes, is discussed here, in the context of total sugars intake. See related article by Freedman et al., p. 1227
Los estilos APA, Harvard, Vancouver, ISO, etc.
Más fuentes

Tesis sobre el tema "Biomarkers"

1

Takala, H. (Heikki). "Biomarkers in esophageal cancer". Doctoral thesis, Oulun yliopisto, 2012. http://urn.fi/urn:isbn:9789514298400.

Texto completo
Resumen
Abstract Mediators of epithelial permeability, angiogenesis and invasion may serve as prognostic indicators and targets for therapies in esophageal cancer (EC). The expressions of claudins, hypoxia inducible factor-1α (HIF-1α), vascular endothelial growth factor-A (VEGF), nitric oxide synthases (iNOS, eNOS, nNOS) and toll-like receptor 9 (TLR9) were evaluated by immunohistochemistry in EC. The results were compared with clinicopathological variables, tumor proliferation and apoptosis. All of the claudins were expressed in most of the cancers. Esophageal adenocarcinomas (EAC) displayed more often increased claudin 3 and 5 expression than esophageal squamous cell carcinomas (ESCC). Loss of claudin 3 expression associated with distant metastases in EC and a tendency in this direction was also observed for claudin 4. Cancers with stronger claudin 4 expression showed increased apoptosis in both EAC and ESCC. HIF-1α was present in most of the ECs and like iNOS more often in ESCC than in EAC. Strong HIF-1α expression tended to associate with positive VEGF immunostaining. In ESCC, both strong HIF-1α expression and VEGF positivity tended to associate with increased microvessel density (MVD). In EAC, tumors showing VEGF positivity associated with increased MVD outside the tumor. Patients with strong HIF-1α expression had more often distant metastases than other patients in EC. There was no VEGF expression in normal esophageal mucosa and T3-4 tumors tended to be more often VEGF positive than T1-2 tumors. The expression of TLR9 was more intensive in dysplasia than in normal epithelium and ESCC and abundant TLR9 expression could serve as a marker of squamous cell high grade dysplasia. Intensive TLR9 expression was associated with higher grade tumors and the presence of nodal and distant metastases in ESCC. EC and its progression may be related to increased angiogenesis regulated by VEGF and HIF-1α. In EC, claudin expression varies along with the histology of the tumor. Claudin expression may be associated with apoptosis or proliferation and contribute to tumor behavior. An association was detected between moderate to strong expression of claudin 3 and a high TLR9 histoscore in ESCC. Altered expression of claudin 3 may result to upregulation of endosomal TLR9. TLR9 may serve as a marker for squamous cell dysplasia and ESCC progression
Tiivistelmä Solukerrosten läpäisevyyttä, verisuonten uudismuodostusta ja kasvainsolujen liikkuvuutta säätelevät tekijät voivat toimia ruokatorvisyövän ennustetekijöinä ja hoidon kohteina. Tässä tutkimuksessa selvitettiin klaudiinien, hypoksia-indusoituvan tekijän 1α (HIF-1α), verisuonen endoteelin kasvutekijän A (VEGF), kolmen typpioksidisyntaasin (iNOS, eNOS ja nNOS) sekä tollin kaltaisen reseptorin 9 (TLR9) ilmentymistä ja merkitystä ruokatorvisyövässä immunohistokemiallisin menetelmin. Tuloksia arvioitiin suhteessa proliferaatioon ja apoptoosiin. Useimmat syöpäkasvaimet ilmensivät jokaista tutkittua klaudiinia. Ruokatorven rauhassyövässä ilmeni levyepiteelisyöpää useammin klaudiineja 3 ja 5. Klaudiinin 3 vähäinen ilmentyminen oli yhteydessä etäpesäkkeiseen tautiin. Sama suuntaus näkyi klaudiinin 4 kohdalla. Apoptoosia todettiin enemmän kasvaimissa, jotka ilmensivät muita enemmän klaudiini 4:ä. Useimmat syöpäkasvaimet ilmensivät HIF-1α:a. Sekä iNOS että HIF-1α ilmentyivät runsaammin levyepiteeli- kuin rauhassyövässä. Tutkimus viittasi yhteyteen voimakkaan HIF-1α:n ilmentymisen ja VEGF:n ilmentymisen välillä. Voimakas HIF-1α:n ilmentyminen ja VEGF:n ilmentyminen vaikuttivat liittyvän ruokatorven levyepiteelisyövän uudissuonituksen lisääntymiseen. Rauhassyövän lisääntynyt uudissuonitus kasvaimen ulkopuolella saattaa liittyä VEGF:n ilmentymiseen. Potilailla, joiden kasvaimissa HIF-1α:n ilmentyminen oli voimakasta, todettiin etäpesäkkeitä muita useammin. VEGF:a ei todettu normaalissa limakalvossa, ja sen ilmentyminen vaikutti olevan yleisempää syvälle kasvavissa kuin pinnallisissa syövissä. TLR9 ilmentyi voimakkaammin levyepiteelin dysplasiassa kuin normaalissa tai kasvainepiteelissä. Huonosti erilaistuvissa ja levinneissä kasvaimissa TLR9 ilmentyi voimakkaammin kuin muissa kasvaimissa. Ruokatorvisyövän synty ja eteneminen voivat liittyä HIF:n ja VEGF:n säätelemään verisuonten uudismuodostukseen. Klaudiinit saattavat vaikuttaa syövän käyttäytymiseen myös apoptoosin ja proliferaation kautta. Tutkimuksessa todettiin yhteys lisääntyneen klaudiinin 3 ilmentymisen ja voimakkaasti ilmentyvän TLR9:n välillä. Muutos klaudiinin 3 ilmentymisessä saattaa lisätä levyepiteelin läpäisevyyttä johtaen TLR9:n aktivoitumiseen. TLR9 voi vaikuttaa ruokatorven levyepiteelin dysplasian ja syövän syntyyn sekä toimia vaikean dysplasian ja aggressiivisen levyepiteelisyövän merkkiaineena
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Blyth, Alison. "Lipid biomarkers in speleothems". Thesis, University of Newcastle Upon Tyne, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.435638.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Scott-Fordsmand, Janeck James. "Biomarkers of soil contamination". Thesis, University of Reading, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.265176.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Hasan, Nazeeha. "Biomarkers for ischaemic stroke". Thesis, Imperial College London, 2013. http://hdl.handle.net/10044/1/27254.

Texto completo
Resumen
Background: Current diagnostic, prognostic and risk stratification tools are inadequate for effective ischaemic stroke management. Hypothesising that -omics approaches can be used to detect novel candidate biomarkers for ischaemic stroke, this thesis aimed to evaluate the current status of biomarkers for ischaemic stroke and develop strategies for biomarker discovery. Methods: Systematic literature review and individual patient data meta-analyses were performed to assess current candidate biomarkers associated with ischaemic stroke. Proteomic SELDI-TOF MS profiling was undertaken to identify novel blood-based protein biomarkers for the diagnosis of acute ischaemic stroke, consisting of a pilot study and a subsequent well-powered discovery study of 104 patients. In an integrative genomics study, transcriptomics data from carotid endarterectomy samples was combined with a genome-wide association study meta-analysis and subjected to functional enrichment analysis to detect differential gene expression or alternative splicing profiles that may be under the control of a genetic variant. Results: Systematic review and meta-analysis concluded that no current candidate biomarkers could be recommended for routine clinical practice, supporting the pursuit of novel biomarkers for ischaemic stroke and informing the design of subsequent experimental studies. SELDI-TOF MS detected two plasma protein ions, m/z 3699 and m/z 6640, which could differentiate between acute cerebral ischaemia and stroke mimics. Protein ion m/z 6640, identified as ApoC 1, highlighted the role of lipid dysregulation and was postulated to be a novel candidate biomarker for acute cerebral ischaemia. Integrative genomics provided evidence for the genetic regulation of cytoskeletal organisation and extracellular matrix remodelling processes in carotid disease. The LTBP4 gene was found to be a candidate risk biomarker for ischaemic stroke by predicting plaque instability and rupture. Conclusions: This work provides workflows for successful biomarker discovery using innovative -omics approaches, highlights key pathogenic pathways and identifies novel candidate biomarkers for ischaemic stroke diagnosis and risk stratification.
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Alhilal, Maryam. "Biomarkers of fat intake". Thesis, King's College London (University of London), 2013. https://kclpure.kcl.ac.uk/portal/en/theses/biomarkers-of-fat-intake(32ce2b69-77d6-4cc8-93d7-2d9c38b6f9d4).html.

Texto completo
Resumen
The thesis reviews the previous use of biomarkers of fatty acid intake and concludes that there is a lack of supporting evidence from large randomized controlled trials (RCT) of sufficient duration for their use to be justified. The hypothesis that fatty acid biomarkers are robust indices of the intake certain fatty acids was tested by the analysis of blood samples from three large and long-term RCTs where dietary intake had been well controlled and compared with a control treatment. Erythrocyte lipid fatty acid composition was unable to detect changes in saturated fatty acid (SFA) or oleic acid intake. Plasma total lipids and phospholipids SFA were also poor indicators of SFA intake. The intake of n-3 long-chain polyunsaturated fatty acids (LC-PUFA) could be predicted from the proportions in plasma and erythrocytes. Principal components analysis appeared to be a valid data reduction technique to measure changes in fatty acid patterns. A co-twin study design conducted in 570 female participants enrolled in the St Thomas‟ Twins Study investigated the heritability of fatty acid biomarkers (adipose tissue and plasma). For most fatty acids, environmental factors (dietary intake) were dominant, but in the case of arachidonic acid, 65% of the variance was explained by additive genetic factors. Investigations subsequently explored the effects of variations in single nucleotide polymorphisms (SNP) in the fatty acid desaturase (FADS) genes on the fatty acid composition of the biomarkers. Polymorphism in FADS1 rs174537 explained some of this variation. Carriage of the minor allele of rs174537 SNP also influenced the proportions of n-6 LC-PUFA in an RCT. Further research is suggested to identify what appeared to be a FADS1/FADS2 haplotype predicting lower levels of LC-PUFA, which might be of public health significance. In conclusion, plasma fatty acid composition can be recommended to elucidate the potential relationships between polyunsaturated, trans-unsaturated and branched chain fatty acid intake and non-communicable diseases.
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Esteves, Eduardo Jorge Mónica. "Biomarkers in Ovis aries". Master's thesis, Universidade de Aveiro, 2014. http://hdl.handle.net/10773/14034.

Texto completo
Resumen
Mestrado em Biologia Molecular e Celular
Ferramentas que armazenem e procedam à catalogação das proteínas identificadas em proteomas resultantes de amostras de tecidos diversos recolhidos a partir de indivíduos representativos de situações fisiológicas e patológicas, constituem instrumentos poderosos para a integração da informação já publicada. Muita informação sobre os mecanismos moleculares subjacentes a patologias pode hoje ser gerada a partir de estratégias bioinformáticas. No âmbito de projetos anteriormente desenvolvidos foi construída uma base de dados, o OralOme. O presente trabalho tem como objetivo a criação de uma base de dados, o OvinOme, aplicando a mesma metodologia desenvolvida para saúde humana, agora para o armazenamento e catalogação de proteínas identificadas a partir dos proteomas parciais de Ovis aries. A criação desta ferramenta bioinformática contribuirá para o desenvolvimento de métodos de diagnóstico em vida, capazes de detetar as principais patologias que grassam nos rebanhos de ovelhas Serra da Estrela. O desenvolvimento da base de dados passa pelo compilar manual das proteínas identificadas pelos vários estudos publicados relativamente a Ovis aries, anotando toda a informação relativa à caracterização do individuo dador da amostra, tipo de amostra biológica, técnicas utilizadas para a identificação das proteínas e toda a informação conhecida relativa a cada proteína catalogada. O desenvolvimento de um método de diagnóstico em vida passa pela concepção de protocolos de colheita, armazenamento e caracterização da qualidade da amostra. Assim no âmbito de presente trabalho foi também objectivo o desenvolvimento de toda a estratégia para recolha de amostras de saliva em ovinos, transporte, armazenamento e avaliação da qualidade da amostra. A criação de um banco de saliva de rebanhos de ovelhas Serra da Estrela será um objectivo a cumprir em termos de futuro, visando o estabelecimento do diagnóstico precoce utilizando a saliva como fluído para avaliação de proteínas que identifiquem cada patologia, determinadas por análise in silico recorrendo á ferramenta bioinformática OvinOme desenvolvida no âmbito do presente trabalho.
Tools that store and proceed to the cataloging of proteins identified in proteomes derived from samples of various tissues collected from individuals representative of physiological and pathological situations, are powerful tools for the integration of information already published. Much information about the molecular mechanisms underlying pathologies can now be generated from bioinformatic strategies. Under previously developed design was built a database, the OralOme. This work aims to create a database, the OvisOme, applying the same methodology developed for human health now for storage and cataloging of proteins identified from the partial proteomes of Ovis aries. The creation of this bioinformatics tool will contribute to the development of diagnostic methods in life, able to detect major diseases that are rife in flocks of sheep Serra da Estrela. The development database is compiled by the proteins identified by several studies published for manual Ovis aries, noting all the information on the individual characteristics of the donor of the sample, type of biological sample, techniques for identifying proteins and whole known information cataloged for each protein. The development of a method of diagnosis in living passes through the design of the harvesting, storage and characterization of the quality of the sample protocols. So within this study was also aimed at developing the whole strategy for collecting samples of saliva in sheep, transport, storage and evaluation of sample quality. The creation of a database of flocks of sheep saliva Serra da Estrela is a key objective for the future, for the establishment of early diagnosis using saliva as a fluid for evaluation of proteins that identify each pathology, determined by in silico analysis using OvisOme bioinformatics tool developed under this work.
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Keane, Colm. "Novel Biomarkers in DLBCL". Thesis, Griffith University, 2015. http://hdl.handle.net/10072/365557.

Texto completo
Resumen
Diffuse large B cell lymphoma (DLBCL) is the commonest aggressive lymphoma. Despite the advent of combined chemo-­‐immunotherapy, one third of patients still die from their disease. Prognostication of the disease still relies on a clinical scoring system known as the International Prognostic Index (IPI). This divides patients into risk categories. However marked heterogeneity within IPI sub-­‐categories persist. The IPI is a clinical score based predominantly on estimates of patient fitness and tumour burden, but does not utilize information regarding the biology of the tumour cell or the immune tumour microenvironment (TME), in which the malignant B cells reside. The latter is the focus of this thesis. The anti-­‐CD20 monoclonal antibody rituximab has improved the outcome for patients with DLBCL, however the impact of host genetics on its effectiveness is still unclear. The mechanisms of action for rituximab include antibody dependent cytotoxicity (ADCC) and complement mediated cytotoxicity (CDC). Recent reports suggest genetic polymorphisms in the FCGR3A receptor (expressed on NK-­‐cells and monocytes which mediate ADCC) may be a predictor of event free and overall survival in B-­‐cell lymphoma. Data also implicates the same polymorphism in the susceptibility to rituximab induced late-­‐onset neutropenia (LON). There remains no data on the impact of genetic polymorphisms on either outcome or LON in genes involved in the CDC pathway such as C1qA. One hundred and fifteen DLBCL patients treated with ‘Ru CHOP’ (rituximab/cyclophosphamide/vincristine/doxorubicin/prednisolone) chemou immunotherapy were compared with 105 healthy Caucasian controls with regards to FCGR3Aq V158F and C1qAq A276G polymorphisms. Event free and overall survival (EFS and OS) and LON incidence were analysed for linkage to either polymorphism.
Thesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Medical Science
Griffith Health
Full Text
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Andersson, Martina. "Local, intestinal biomarkers for early detection of colorectal cancer". Thesis, Uppsala universitet, Institutionen för farmaci, 2021. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-445701.

Texto completo
Resumen
Colorectal cancer (CRC) is one of the deadliest cancers in the world. The early stage of the disease is usually asymptomatic and therefore screening methods for colorectal cancer need to improve. There is a need for early detection of CRC as treatment is less effective in the advanced stage of the disease.  The current standard screening methods are endoscopy and fecal immunochemical blood tests. Endoscopy is a commonly used method to diagnose the patient, but it is costly, time consuming, and rather unpopular for the patients. An alternative could be to develop targeted molecular imaging probes that specifically deliver agents for example magnetic resonance imaging to colon adenomas and adenocarcinomas. This alternative would be non-invasive and able to detect the disease before morphological changes become evident. Biomarkers are used as an objective indicator of an altered biological process. Here, a literature study was conducted to identify protein biomarkers that are overexpressed in early stages of CRC. This study has focused on biomarkers that could be used to target imaging agents to cancerous lesions. Thus, the biomarkers need to be membrane-bound and expressed on the luminal side of the gastrointestinal tract. This will help future research to develop orally administered targeted imaging probes. Furthermore, a smaller literature search was conducted to identify cell and mouse models representing early stages of CRC. This was done to facilitate translational research going from in vitro to in vivo. Ideally the same protein is available in cell lines, mouse models and humans to enable translational research. This work has resulted in the selection of 7 different proteins that are upregulated during early stages of CRC. These proteins are potentially apically located and therefore possible targets for monoclonal antibodies. These findings might lead to a novel way for preventive patient screening and hopefully reduce the mortality for colorectal cancer.
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Kant, Prashant. "Changes in biomarkers of colorectal cancer risk and biomarkers of inflammation following weight loss". Thesis, University of Leeds, 2012. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.590418.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Liu, Faye Fang. "Biomarkers for chronic arsenic poisoning /". [St. Lucia, Qld.], 2004. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe18519.pdf.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
Más fuentes

Libros sobre el tema "Biomarkers"

1

Peakall, David B. y Lee R. Shugart, eds. Biomarkers. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-84631-1.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Evans, Williams. Biomarkers. New York: S & S, 1991.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Deep, Gagan, ed. Cancer Biomarkers. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-1896-7.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Martí-Bonmatí, Luis y Angel Alberich-Bayarri, eds. Imaging Biomarkers. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43504-6.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Morrow, David A., ed. Cardiovascular Biomarkers. Totowa, NJ: Humana Press, 2006. http://dx.doi.org/10.1007/978-1-59745-051-5.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Peplow, Philip V., Bridget Martinez y Svetlana A. Dambinova, eds. Stroke Biomarkers. New York, NY: Springer New York, 2020. http://dx.doi.org/10.1007/978-1-4939-9682-7.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Maisel, Alan S. y Allan S. Jaffe, eds. Cardiac Biomarkers. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-42982-3.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Salvi, Samanta y Valentina Casadio, eds. Urinary Biomarkers. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-1354-2.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Nass, Sharyl J. y Harold L. Moses, eds. Cancer Biomarkers. Washington, D.C.: National Academies Press, 2007. http://dx.doi.org/10.17226/11892.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

1927-, Yen Teh Fu y Moldowan J. M. 1946-, eds. Geochemical biomarkers. Chur: Harwood Academic Publishers, 1988.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
Más fuentes

Capítulos de libros sobre el tema "Biomarkers"

1

Chaubey, Vikas P., Kevin B. Laupland, Christopher B. Colwell, Gina Soriya, Shelden Magder, Jonathan Ball, Jennifer M. DiCocco et al. "Biomarkers". En Encyclopedia of Intensive Care Medicine, 317. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_3038.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Mocellin, Simone. "Biomarkers". En Soft Tissue Tumors, 25–26. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-58710-9_5.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Harbron, Chris. "Biomarkers". En Nonclinical Statistics for Pharmaceutical and Biotechnology Industries, 365–80. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-23558-5_14.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Shetty, Vivek. "Biomarkers". En Encyclopedia of Behavioral Medicine, 257–59. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39903-0_232.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Wideman, Timothy H., Michael J. L. Sullivan, Shuji Inada, David McIntyre, Masayoshi Kumagai, Naoya Yahagi, J. Rick Turner et al. "Biomarkers". En Encyclopedia of Behavioral Medicine, 225–27. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_232.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Debnath, Mousumi, Godavarthi B. K. S. Prasad y Prakash S. Bisen. "Biomarkers". En Molecular Diagnostics: Promises and Possibilities, 287–308. Dordrecht: Springer Netherlands, 2009. http://dx.doi.org/10.1007/978-90-481-3261-4_18.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Mose, Stephan, Stephan Mose, Brandon J. Fisher, Iris Rusu, Charlie Ma, Lu Wang, Larry C. Daugherty et al. "Biomarkers". En Encyclopedia of Radiation Oncology, 28. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-540-85516-3_605.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Javaux, Emmanuelle J. "Biomarkers". En Encyclopedia of Astrobiology, 293. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-44185-5_180.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Devasena T. "Biomarkers". En Therapeutic and Diagnostic Nanomaterials, 29–40. Singapore: Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-0923-5_3.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Weir, David. "Biomarkers". En The Palgrave Handbook of Survey Research, 573–86. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-54395-6_65.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.

Actas de conferencias sobre el tema "Biomarkers"

1

Nogueira, Cristiana Bello Dultra, João Gustavo dos Anjos Morais Oliveira y Alexandre Martins Lopes Filho. "The use of biomarkers in Duchenne muscular dystrophy – a literature review". En XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.330.

Texto completo
Resumen
Background: Biomarkers are indicators associated with a disease, used for diagnosis, monitoring progression and prognosis. In Duchenne Muscular Dystrophy (DMD), they are very important. Although the literature describes various types of biomarkers for it, there is no consensus of their appropriate use. Objective: Describe the use of biomarkers associated with DMD. Methods: This literature review used articles searched in PubMed using the formula: (“Duchenne Muscular Dystrophy”) AND (“Biomarkers”). Those that corroborate with the objective of this review were included. Model’s studies and studies that evaluated biomarkers in other diseases were excluded. Results: Cohort and case-control studies propose a staging score that evaluate the infiltration of fat into the muscles and the edema in magnetic resonance imaging (MRI) sequences. Other studies indicate that the relation between volume and cross-sectional can be a prognostic biomarker. Some clinical trials already use these MRI markers to evaluate the effectiveness of their therapies. Creatine Kinase, a serum marker, has been shown in clinical trials to be a good biomarker in diagnosis’ moment. However, due to its low specificity, it is not used in prognosis. In model studies, miRNAs have been shown to be useful in various spheres, and can be used as biomarkers in muscular dystrophies, helping with diagnosis, staging and treatment. Conclusions: The use of biomarkers in DMD is not well defined, for financial reasons and lack of more concrete evidence. Therefore, further studies are needed.
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Brum, Wagner, Andrei Bieger, Joao Pedro Ferrari Souza, Marco de Bastiani, Andrea Benedet, Nicholas Ashton, Tharick Pascoal et al. "A THREE-RANGE APPROACH ENHANCES PROGNOSTIC UTILITY OF CSF BIOMARKERS IN ALZHEIMER’S DISEASE". En XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda022.

Texto completo
Resumen
Background: Alzheimer’s disease (AD) was biologically defined by the 2018 NIA-AA Research Framework (RF), which recommends dichotomously defining biomarker status as normal or abnormal with single cutpoints. However, a three-range approach remains unexplored in AD fluid biomarkers. Objective: To assess the prognostic utility of a three-range approach for CSF biomarkers in AD. Methods: We included 1278 non-demented individuals (CU: n=575; MCI: n=703) from the ADNI with baseline CSF Elecsys® biomarkers. Within it, we defined three-range cutpoints with two-graph receiver operating characteristics (TGROC) for each CSF biomarker (Aβ1-42, p-tau, p-tau/Aβ1-42), based on amyloid PET positivity. Then, linear mixed-effects and Cox proportional hazards models were used to estimate longitudinal cognitive trajectories and risk of clinical progression based on CSF biomarker status. Hereby derived three-range cutpoints were compared to previously described binary thresholds for the same biomarkers. Power analyses for simulated trials were also carried. Results: We observed dynamic amyloid-PET changes for participants in the intermediate range, while a static profile for clearly normal and abnormal groups. Longitudinally, our approach revealed a divergent intermediate cognitive trajectory undetected by dichotomization, with power analyses demonstrating potential applications for trial enrichment. Conclusion: The proposed approach can improve CSF-based diagnosis, refine prognostic assessment and enhance clinical trial recruitment.
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Corrie, Simon R., Jacob W. Coffey y Mark A. F. Kendall. "In Vivo Biomarker Capture via the Skin Using Surface-Modified Microprojection Arrays". En ASME 2013 2nd Global Congress on NanoEngineering for Medicine and Biology. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/nemb2013-93215.

Texto completo
Resumen
Whilst blood is the sample most often collected for diagnostic purposes, testing is complicated by the need to purify or concentrate biomarkers prior to detection. While needle/syringe or lancet technology is most often used for bulk sample collection, devices have not yet been developed that selectively capture biomarkers of interest in vivo, simplifying downstream detection requirements. Our group developed the Micropatch Array — a device comprising an array of microprojections which breach the outer layers of the skin to selectively capture biomarkers from the dermis. In this presentation we will describe our emerging data focused on the mechanisms of biomarker capture in vivo, and our investigations into improving the capture efficiency of the devices for important biomarkers.
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Kallingal, Nithusha, Kishor Kumar Sadasivuni, Issam Bahadur, Huseyin Cagatay Yalcin, Asiya Al-Busaidi, Hassen M. Ouakad y Somaya Al-Maadeed. "Colorimetry-based Detection of Exhaled Breath Biomarkers for Predicting Heart Failure". En Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0077.

Texto completo
Resumen
The exhaled breath volatile organic compounds (VOC’s) represent a biosignature with the potential to identify and describe heart failure diseases. Exhaled Breath biomarkers-based diagnosis of heart diseases may be easier and earlier detection than other available techniques. So, this is a review of combining both exhaled breath analysis with cost effective colorimetry technology to detect biomarkers for heart failure diseases. We also studied the effectiveness of biomarker trimethyl amine for cardiovascular diseases detection.
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Sathija, P. K., S. Rajaram, V. K. Arora, B. Gupta y N. Goel. "Evaluation of biomarkers p16ink4a/ki-67 in cervical cytology for diagnosis of cervical intraepithelial neoplasia". En 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685267.

Texto completo
Resumen
Background: Novel biomarkers, P16INK4a/Ki-67 are disease specific and identify risk of progression to cervical cancer. Aim: To test the clinical utility of biomarkers p16INK4a/Ki-67 in cervical intraepithelial neoplasia. Methodology: Experimental study was conducted over an 18 month period at a tertiary care hospital. 3500 sexually active women between 30-55 years were screened by VIA/VILI, Pap test & HPV-DNA PCR. All screen positive women (n=280) underwent colposcopy and biopsy if required. At the time of colposcopy repeat cervical smear were taken for evaluation of p16INK4a/Ki-67. Immunocytochemistry for p16INK4A and Ki-67 was done by partitioning one slide into two parts for each biomarker. For p16INK4A positivity, nuclear +/- cytoplasmic scoring and intensity score was calculated and final score obtained. For Ki-67 staining was exclusively nuclear. Staining patterns were categorized as negative, intermediate or strongly positive. Results: 86 women with abnormal cytology were evaluated with p16INK4A/Ki-67 immunocytochemistry and 20.9% (n=18) and 18.6% (n=16) were positive for each biomarker. For ASCUS (n=42) and LSIL (n=23) smears, specificity and NPV were 100% with a likelihood ratio (LR+) of 27 and 25 respectively suggesting good diagnostic accuracy. The combined sensitivity and specificity of p16INK4a/Ki-67 in detecting CIN-2+ lesion was 76.9% and 95.8% respectively with LR+ of 18.72 in high grade smears. Conclusions: p16INK4A/Ki-67 evaluation in cervical cytology are valuable biomarkers in ruling out or detecting CIN2+ in ASCUS and LSIL smears. Unnecessary intervention in large number of low grade smears can be avoided by applying these biomarkers. In high grade smears detection rate of biomarkers p16INK4A/Ki-67 was high and had a good diagnostic accuracy.
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Wu, Liangliang, Xinyan Fang, Bin Cheng y Ansong Geng. "Occluded Biomarkers or Covalently Bound Biomarkers?" En 29th International Meeting on Organic Geochemistry. European Association of Geoscientists & Engineers, 2019. http://dx.doi.org/10.3997/2214-4609.201902695.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Collins, Hannah, Rahul Pal, Murali Krishnamoorthy, Thinzar Lwin, Eben L. Rosenthal, Patrick Wagner y Anand T. N. Kumar. "Fluorescence Lifetime (FLT)-Enhanced Tumor Imaging with Biomarker-Targeted Agents". En Clinical and Translational Biophotonics. Washington, D.C.: Optica Publishing Group, 2024. http://dx.doi.org/10.1364/translational.2024.ts5b.2.

Texto completo
Resumen
Fluorescence lifetime (FLT) imaging of biomarker-targeted probes enhances tumor identification accuracy compared to fluorescence intensity. We demonstrate using microscopy that FLT of diverse probes, acting via molecular expression or physiological biomarkers, enables cellular-resolution tumor identification.
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Wadduwage, Dushan N. "Stochastic Proof by Contradiction Complements Machine-learning-driven Biomarker Discovery in Image Data". En Clinical and Translational Biophotonics. Washington, D.C.: Optica Publishing Group, 2024. http://dx.doi.org/10.1364/translational.2024.jm4a.55.

Texto completo
Resumen
Given image data, machine-learning-based classifiers “discover” biomarkers under the hypothesis they exist; This is suspectable to confirmation bias. Instead, we propose an approach to disprove the null hypothesis of non-existence, countering bias in biomarker discovery.
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Goncharov, Artem, Hyou-Arm Joung, Rajesh Ghosh, Gyeo-Re Han, Zachary S. Ballard, Quinn Maloney, Alexandra Bell et al. "Fluorescence-based multiplexed point-of-care sensor using deep learning". En Bio-Optics: Design and Application. Washington, D.C.: Optica Publishing Group, 2023. http://dx.doi.org/10.1364/boda.2023.dtu3a.7.

Texto completo
Resumen
We present a multiplexed paper-based point-of-care sensor processed by a hand-held fluorescence reader and neural networks that quantify three cardiovascular disease biomarkers from human serum samples, achieving a limit-of-detection of ≤0.52 ng/mL for each biomarker.
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Burenkov, I. A., J. Sabines-Chesterking y S. V. Polyakov. "Resolving Single Molecules in Flow Cytometer in Presence of Fluorescent Bursts via an Optical Quantum Measurement". En CLEO: Applications and Technology. Washington, D.C.: Optica Publishing Group, 2023. http://dx.doi.org/10.1364/cleo_at.2023.jth2a.37.

Texto completo
Resumen
We prove high signal-to-noise (SNR>6) in single-biomarker detection with a quantum-enabled flow cytometer. We observe the nonclassical signal from single biomarkers and differentiate it from the spurious detection of “bright” classical particles based on experimentally characterized statistical properties and quantum measurement.
Los estilos APA, Harvard, Vancouver, ISO, etc.

Informes sobre el tema "Biomarkers"

1

Atherosclerosis Biomarkers by Computed Tomography Angiography (CTA). Chair Andrew Buckler, Luca Saba y Uwe Joseph Schoepf. Radiological Society of North America (RSNA) / Quantitative Imaging Biomarkers Alliance (QIBA), marzo de 2023. http://dx.doi.org/10.1148/qiba/20230328.

Texto completo
Resumen
The clinical application of Computed Tomography Angiography (CTA) is widely available as a technique to optimize the therapeutic approach to treating vascular disease. Evaluation of atherosclerotic arterial plaque characteristics is currently based on qualitative biomarkers. However, the reproducibility of such findings has historically been limited even among experts (1). Quantitative imaging biomarkers have been shown to have additive value above traditional qualitative imaging metrics and clinical risk scores regarding patient outcomes (2). However, many definitions and cut-offs are present in the current literature; therefore, standardization of quantitative evaluation of CTA datasets is needed before becoming a valuable tool in daily clinical practice. To establish these biomarkers in clinical practice, techniques are required to standardize quantitative imaging across different manufacturers with cross-calibration. Moreover, the post-processing of atherosclerotic plaque segmentation needs to be optimized and standardized. The goal of a Quantitative Imaging Biomarker Alliance (QIBA) Profile is to provide an implementation guide to generate a biomarker with an effective level of performance, mostly by reducing variability and bias in the measurement. The performance claims represent expert consensus and will be empirically demonstrated at a subsequent stage. Users of this Profile are encouraged to refer to the following site to understand the document’s context: http://qibawiki.rsna.org/index.php/QIBA_Profile_Stages. All statistical performance assessments are stated in carefully considered metrics and according to strict definitions as given in (3-8), which also includes detailed, peer-reviewed rationale on the importance of adhering to such standards. The expected performance is expressed as Claims (Section 1.2). To achieve those claims, Actors (Scanners, Reconstruction Software, Image Analysis Tools, Imaging Physicians, Physicists, and Technologists) must meet the Checklist Requirements (Section 3) covering Subject Handling, Image Data Acquisition, Image Data Reconstruction, Image QA, and Image Analysis. This Profile is at the Clinically Feasible stage (qibawiki.rsna.org/index.php/QIBA_Profile_Stages) which indicate that multiple sites have performed the Profile and found it to be practical and expect it to achieve the claimed performance. QIBA Profiles for other CT, MRI, PET, and Ultrasound biomarkers can be found at qibawiki.rsna.org
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Saba, Luca y Uwe Joseph Schoepf. Atherosclerosis Biomarkers by Computed Tomography Angiography (CTA) - Maintenance version June 2024. Chair Andrew Buckler. Radiological Society of North America (RSNA) / Quantitative Imaging Biomarkers Alliance (QIBA), junio de 2024. http://dx.doi.org/10.1148/qiba/202406.

Texto completo
Resumen
The clinical application of Computed Tomography Angiography (CTA) is widely available as a technique to optimize the therapeutic approach to treating vascular disease. Evaluation of atherosclerotic arterial plaque characteristics is currently based on qualitative biomarkers. However, the reproducibility of such findings has historically been limited even among experts. Quantitative imaging biomarkers have been shown to have additive value above traditional qualitative imaging metrics and clinical risk scores regarding patient outcomes. However, many definitions and cut-offs are present in the current literature; therefore, standardization of quantitative evaluation of CTA datasets is needed before becoming a valuable tool in daily clinical practice. To establish these biomarkers in clinical practice, techniques are required to standardize quantitative imaging across different manufacturers with cross-calibration. Moreover, the post-processing of atherosclerotic plaque segmentation needs to be optimized and standardized. The goal of a Quantitative Imaging Biomarker Alliance (QIBA) Profile is to provide an implementation guide to generate a biomarker with an effective level of performance, mostly by reducing variability and bias in the measurement. The performance claims represent expert consensus and will be empirically demonstrated at a subsequent stage. Users of this Profile are encouraged to refer to the following site to understand the document’s context: http://qibawiki.rsna.org/index.php/QIBA_Profile_Stages. All statistical performance assessments are stated in carefully considered metrics and according to strict definitions as given in (3-8), which also includes detailed, peer-reviewed rationale on the importance of adhering to such standards. The expected performance is expressed as Claims (Section 1.2). To achieve those claims, Actors (Scanners, Reconstruction Software, Image Analysis Tools, Imaging Physicians, Physicists, and Technologists) must meet the Checklist Requirements (Section 3) covering Subject Handling, Image Data Acquisition, Image Data Reconstruction, Image QA, and Image Analysis. This Profile is at the Clinically Feasible stage (qibawiki.rsna.org/index.php/QIBA_Profile_Stages) which indicate that multiple sites have performed the Profile and found it to be practical and expect it to achieve the claimed performance. QIBA Profiles for other CT, MRI, PET, and Ultrasound biomarkers can be found at qibawiki.rsna.org.
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Marmar, Charles R. Biomarkers for PTSD. Fort Belvoir, VA: Defense Technical Information Center, julio de 2010. http://dx.doi.org/10.21236/ada618637.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Marmar, Charles. Biomarkers for PTSD. Fort Belvoir, VA: Defense Technical Information Center, julio de 2011. http://dx.doi.org/10.21236/ada618638.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Marmar, Charles R. Biomarkers for PTSD. Fort Belvoir, VA: Defense Technical Information Center, julio de 2012. http://dx.doi.org/10.21236/ada619951.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Zhu, Mucheng, Zhenhua Lu, Hao Guo, Xiaoting Gu, Defang Wei y Zhengyi Zhang. Diagnostic Value of Combination of Biomarkers for Malignant Pleural Mesothelioma：Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, octubre de 2022. http://dx.doi.org/10.37766/inplasy2022.10.0043.

Texto completo
Resumen
Review question / Objective: Tumor biomarkers have become increasingly attractive due to their non-invasive properties and relatively inexpensive nature for early diagnosis of Malignant pleural mesothelioma (MPM) .Many scholars have published studies on DNA and protein as biomarkers for early diagnosis of MPM, which might be a new breakthrough. A new meta-analysis is necessary to compare the accuracy of combination of three kinds of DNA and three kinds of proteins. Condition being studied: XAs the previous studies have a certain controversy about DNA as a biomarker of MPM, we conducted a systematic search using EMBASE, PubMed and Cochrane Library to identify relevant studies from the inception to October 2021. we used QUADAS-2 for Quality Assessment to Diagnostic Accuracy Studies to evaluate the quality of eligible studies. We used Stata 15.0 and Review Manager 5.4 software to perform the meta-analysis to compare the accuracy of combination of three kinds of DNA and three kinds of proteins.
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Marmar, Charles R. Validating Biomarkers for PTSD. Fort Belvoir, VA: Defense Technical Information Center, abril de 2015. http://dx.doi.org/10.21236/ada620325.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Irwin, Courtney L., Patrícia S. Coelho, Bruno Kluwe-Schiavon, Anabela Silva-Fernandes, Óscar F. Gonçalves, Jorge Leite y Sandra Carvalho. Treatment-related changes of molecular biomarkers in major depressive disorder: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, octubre de 2021. http://dx.doi.org/10.37766/inplasy2021.10.0105.

Texto completo
Resumen
Review question / Objective: The aim of this review is two-fold: first, we sought to identify candidate biomarkers that could provide information on whether an individual with MDD would respond positively to common non-pharmacological treatments, and secondly, to conduct a meta-analysis to determine whether one form of common non-pharmacological treatment (namely CBT, tDCS and TMS) would produce better results over another in regards to its influence on biomarker levels. Information sources: The information sources used were: three online databases (PubMed, Scopus, and PsycINFO) to identify English-language human randomised controlled trials unrestricted by year of publication.
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Zelikoff, Judith T. Fish Immune Response as Biomarkers. Fort Belvoir, VA: Defense Technical Information Center, marzo de 2001. http://dx.doi.org/10.21236/ada399403.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Bearman, Gregory H., Darryl J. Bornhop y Richard M. Levenson. Biomarkers and Biological Spectral Imaging. Fort Belvoir, VA: Defense Technical Information Center, enero de 2001. http://dx.doi.org/10.21236/ada409182.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
También puede estar interesado en las bibliografías ampliadas sobre el tema "Biomarkers" para tipos de fuentes particulares:
Artículos de revistas Tesis Libros
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía